Prediction of Clinically Significant Prostate Cancer by a Specific Collagen-related Transcriptome, Proteome, and Urinome Signature.

Cancer aggressiveness Cancer biology Collagen metabolism Machine learning Multiparametric-magnetic resonance imaging Predictive biomarker Prostate cancer detection

Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
07 Jun 2024
Historique:
received: 23 03 2024
revised: 23 04 2024
accepted: 21 05 2024
medline: 9 6 2024
pubmed: 9 6 2024
entrez: 9 6 2024
Statut: aheadofprint

Résumé

While collagen density has been associated with poor outcomes in various cancers, its role in prostate cancer (PCa) remains elusive. Our aim was to analyze collagen-related transcriptomic, proteomic, and urinome alterations in the context of detection of clinically significant PCa (csPCa, International Society of Urological Pathology [ISUP] grade group ≥2). Comprehensive analyses for PCa transcriptome (n = 1393), proteome (n = 104), and urinome (n = 923) data sets focused on 55 collagen-related genes. Investigation of the cellular source of collagen-related transcripts via single-cell RNA sequencing was conducted. Statistical evaluations, clustering, and machine learning models were used for data analysis to identify csPCa signatures. Differential expression of 30 of 55 collagen-related genes and 34 proteins was confirmed in csPCa in comparison to benign prostate tissue or ISUP 1 cancer. A collagen-high cancer cluster exhibited distinct cellular and molecular characteristics, including fibroblast and endothelial cell infiltration, intense extracellular matrix turnover, and enhanced growth factor and inflammatory signaling. Robust collagen-based machine learning models were established to identify csPCa. The models outcompeted prostate-specific antigen (PSA) and age, showing comparable performance to multiparametric magnetic resonance imaging (mpMRI) in predicting csPCa. Of note, the urinome-based collagen model identified four of five csPCa cases among patients with Prostate Imaging-Reporting and Data System (PI-IRADS) 3 lesions, for which the presence of csPCa is considered equivocal. The retrospective character of the study is a limitation. Collagen-related transcriptome, proteome, and urinome signatures exhibited superior accuracy in detecting csPCa in comparison to PSA and age. The collagen signatures, especially in cases of ambiguous lesions on mpMRI, successfully identified csPCa and could potentially reduce unnecessary biopsies. The urinome-based collagen signature represents a promising liquid biopsy tool that requires prospective evaluation to improve the potential of this collagen-based approach to enhance diagnostic precision in PCa for risk stratification and guiding personalized interventions. In our study, collagen-related alterations in tissue, and urine were able to predict the presence of clinically significant prostate cancer at primary diagnosis.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
While collagen density has been associated with poor outcomes in various cancers, its role in prostate cancer (PCa) remains elusive. Our aim was to analyze collagen-related transcriptomic, proteomic, and urinome alterations in the context of detection of clinically significant PCa (csPCa, International Society of Urological Pathology [ISUP] grade group ≥2).
METHODS METHODS
Comprehensive analyses for PCa transcriptome (n = 1393), proteome (n = 104), and urinome (n = 923) data sets focused on 55 collagen-related genes. Investigation of the cellular source of collagen-related transcripts via single-cell RNA sequencing was conducted. Statistical evaluations, clustering, and machine learning models were used for data analysis to identify csPCa signatures.
KEY FINDINGS AND LIMITATIONS UNASSIGNED
Differential expression of 30 of 55 collagen-related genes and 34 proteins was confirmed in csPCa in comparison to benign prostate tissue or ISUP 1 cancer. A collagen-high cancer cluster exhibited distinct cellular and molecular characteristics, including fibroblast and endothelial cell infiltration, intense extracellular matrix turnover, and enhanced growth factor and inflammatory signaling. Robust collagen-based machine learning models were established to identify csPCa. The models outcompeted prostate-specific antigen (PSA) and age, showing comparable performance to multiparametric magnetic resonance imaging (mpMRI) in predicting csPCa. Of note, the urinome-based collagen model identified four of five csPCa cases among patients with Prostate Imaging-Reporting and Data System (PI-IRADS) 3 lesions, for which the presence of csPCa is considered equivocal. The retrospective character of the study is a limitation.
CONCLUSIONS AND CLINICAL IMPLICATIONS CONCLUSIONS
Collagen-related transcriptome, proteome, and urinome signatures exhibited superior accuracy in detecting csPCa in comparison to PSA and age. The collagen signatures, especially in cases of ambiguous lesions on mpMRI, successfully identified csPCa and could potentially reduce unnecessary biopsies. The urinome-based collagen signature represents a promising liquid biopsy tool that requires prospective evaluation to improve the potential of this collagen-based approach to enhance diagnostic precision in PCa for risk stratification and guiding personalized interventions.
PATIENT SUMMARY RESULTS
In our study, collagen-related alterations in tissue, and urine were able to predict the presence of clinically significant prostate cancer at primary diagnosis.

Identifiants

pubmed: 38851995
pii: S2588-9311(24)00144-5
doi: 10.1016/j.euo.2024.05.014
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Isabel Heidegger (I)

Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: Isabel-maria.heidegger@i-med.ac.at.

Maria Frantzi (M)

Department of Biomarker Research, Mosaiques Diagnostics GmbH, Hannover, Germany.

Stefan Salcher (S)

Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Piotr Tymoszuk (P)

Data Analytics As a Service Tirol, Wörgl, Austria.

Agnieszka Martowicz (A)

Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Enrique Gomez-Gomez (E)

Urology Department, Reina Sofía University Hospital, Maimonides Institute of Biomedical Research of Cordoba, University of Cordoba, Cordoba, Spain.

Ana Blanca (A)

Urology Department, Reina Sofía University Hospital, Maimonides Institute of Biomedical Research of Cordoba, University of Cordoba, Cordoba, Spain.

Guillermo Lendinez Cano (G)

Urology Department, Biomedical Institute of Seville, University Hospital Virgen del Rocío, Seville, Spain.

Agnieszka Latosinska (A)

Department of Biomarker Research, Mosaiques Diagnostics GmbH, Hannover, Germany.

Harald Mischak (H)

Department of Biomarker Research, Mosaiques Diagnostics GmbH, Hannover, Germany.

Antonia Vlahou (A)

Systems Biology Center, Biomedical Research Foundation, Academy of Athens, Athens, Greece.

Christian Langer (C)

Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria.

Friedrich Aigner (F)

Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria.

Martin Puhr (M)

Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.

Anne Krogsdam (A)

Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.

Zlatko Trajanoski (Z)

Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.

Dominik Wolf (D)

Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Andreas Pircher (A)

Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: andreas.pircher@i-med.ac.at.

Classifications MeSH